Rosa L de Jager1, Erik M van Maarseveen2, Michiel L Bots3, Peter J Blankestijn1. 1. Department of Nephrology & Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands. 2. Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands. 3. The Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract
AIMS: Hypertension is only controlled in approximately 35% of the patients, which could be partially due to nonadherence. Recently, bioanalytical assessment of adherence to blood pressure (BP) lowering drugs has gaining interest. Our aim was to explore possible determinants of nonadherence in treatment resistant hypertension, assessed by objective screening for antihypertensive agents in serum. The secondary aim was to study the effect of adherence on the change in BP. METHODS: This project was a substudy of SYMPATHY; an open-label randomized-controlled trial to assess the effect of renal denervation on BP 6 months after treatment compared to usual care in patients with resistant hypertension. Stored serum samples were screened for antihypertensive agents to assess adherence at baseline and 6 months after intervention, using liquid chromatography-tandem mass spectrometry. Office and 24-h BP were measured on the same day as blood was sampled. Patients and physicians were unaware of adherence measurements. RESULTS: Ninety-eight baseline and 83 6-month samples were available for analysis. Sixty-eight percent [95% confidence interval (CI) 59-78%] of the patients was nonadherent (n = 67). For every onw pill more prescribed, 0.785 [95%CI 0.529-0.891] prescribed pill was less detected in blood. A decrease of one pill in adherence between baseline and 6 months was associated with a significant rise in office systolic BP of 4 (95%CI 0.230-8.932) mmHg. CONCLUSION: Objective measurement of BP lowering drugs in serum, as a tool to assess adherence, showed that nonadherence was very common in patients with apparent resistant hypertension. Furthermore, the assessment results were related to (changes in) blood pressure. Our findings provide direct and objective methodology to help the physician to understand and to improve the condition of apparent resistant hypertension.
RCT Entities:
AIMS: Hypertension is only controlled in approximately 35% of the patients, which could be partially due to nonadherence. Recently, bioanalytical assessment of adherence to blood pressure (BP) lowering drugs has gaining interest. Our aim was to explore possible determinants of nonadherence in treatment resistant hypertension, assessed by objective screening for antihypertensive agents in serum. The secondary aim was to study the effect of adherence on the change in BP. METHODS: This project was a substudy of SYMPATHY; an open-label randomized-controlled trial to assess the effect of renal denervation on BP 6 months after treatment compared to usual care in patients with resistant hypertension. Stored serum samples were screened for antihypertensive agents to assess adherence at baseline and 6 months after intervention, using liquid chromatography-tandem mass spectrometry. Office and 24-h BP were measured on the same day as blood was sampled. Patients and physicians were unaware of adherence measurements. RESULTS: Ninety-eight baseline and 83 6-month samples were available for analysis. Sixty-eight percent [95% confidence interval (CI) 59-78%] of the patients was nonadherent (n = 67). For every onw pill more prescribed, 0.785 [95%CI 0.529-0.891] prescribed pill was less detected in blood. A decrease of one pill in adherence between baseline and 6 months was associated with a significant rise in office systolic BP of 4 (95%CI 0.230-8.932) mmHg. CONCLUSION: Objective measurement of BP lowering drugs in serum, as a tool to assess adherence, showed that nonadherence was very common in patients with apparent resistant hypertension. Furthermore, the assessment results were related to (changes in) blood pressure. Our findings provide direct and objective methodology to help the physician to understand and to improve the condition of apparent resistant hypertension.
Authors: Mohammad H Forouzanfar; Patrick Liu; Gregory A Roth; Marie Ng; Stan Biryukov; Laurie Marczak; Lily Alexander; Kara Estep; Kalkidan Hassen Abate; Tomi F Akinyemiju; Raghib Ali; Nelson Alvis-Guzman; Peter Azzopardi; Amitava Banerjee; Till Bärnighausen; Arindam Basu; Tolesa Bekele; Derrick A Bennett; Sibhatu Biadgilign; Ferrán Catalá-López; Valery L Feigin; Joao C Fernandes; Florian Fischer; Alemseged Aregay Gebru; Philimon Gona; Rajeev Gupta; Graeme J Hankey; Jost B Jonas; Suzanne E Judd; Young-Ho Khang; Ardeshir Khosravi; Yun Jin Kim; Ruth W Kimokoti; Yoshihiro Kokubo; Dhaval Kolte; Alan Lopez; Paulo A Lotufo; Reza Malekzadeh; Yohannes Adama Melaku; George A Mensah; Awoke Misganaw; Ali H Mokdad; Andrew E Moran; Haseeb Nawaz; Bruce Neal; Frida Namnyak Ngalesoni; Takayoshi Ohkubo; Farshad Pourmalek; Anwar Rafay; Rajesh Kumar Rai; David Rojas-Rueda; Uchechukwu K Sampson; Itamar S Santos; Monika Sawhney; Aletta E Schutte; Sadaf G Sepanlou; Girma Temam Shifa; Ivy Shiue; Bemnet Amare Tedla; Amanda G Thrift; Marcello Tonelli; Thomas Truelsen; Nikolaos Tsilimparis; Kingsley Nnanna Ukwaja; Olalekan A Uthman; Tommi Vasankari; Narayanaswamy Venketasubramanian; Vasiliy Victorovich Vlassov; Theo Vos; Ronny Westerman; Lijing L Yan; Yuichiro Yano; Naohiro Yonemoto; Maysaa El Sayed Zaki; Christopher J L Murray Journal: JAMA Date: 2017-01-10 Impact factor: 56.272
Authors: Oliver Jung; Janis L Gechter; Cora Wunder; Alexander Paulke; Christine Bartel; Helmut Geiger; Stefan W Toennes Journal: J Hypertens Date: 2013-04 Impact factor: 4.844
Authors: Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi Journal: Lancet Date: 2015-12-24 Impact factor: 79.321
Authors: Sebastian Ewen; Markus R Meyer; Bodo Cremers; Ulrich Laufs; Andreas G Helfer; Dominik Linz; Ingrid Kindermann; Christian Ukena; Michel Burnier; Stefan Wagenpfeil; Hans H Maurer; Michael Böhm; Felix Mahfoud Journal: Clin Res Cardiol Date: 2015-08-26 Impact factor: 5.460
Authors: Anna Pisano; Luigi Francesco Iannone; Antonio Leo; Emilio Russo; Giuseppe Coppolino; Davide Bolignano Journal: Cochrane Database Syst Rev Date: 2021-11-22
Authors: Jelle M Beernink; Milou M Oosterwijk; Kamlesh Khunti; Pankaj Gupta; Prashanth Patel; Job F M van Boven; Hiddo J Lambers Heerspink; Stephan J L Bakker; Gerjan Navis; Roos M Nijboer; Gozewijn D Laverman Journal: Diabetes Care Date: 2021-04-23 Impact factor: 17.152